Integrated Nanopore and short-read RNA sequencing identifies dysregulation of METTL3- m6A modifications in endocrine therapy- sensitive and resistant breast cancer cells
Functional & Integrative Genomics · 2025
DOI: 10.1007/s10142-025-01658-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Functional & Integrative Genomics, 2025. Verfasst von Belinda J Petri und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Resistance, Neoplasm, Methyltransferases, Adenosine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, National Institutes of Health National Institute of General Medical Sciences.
Abstract (Originalsprache)
The role of epitranscriptomic changes in the development of acquired endocrine therapy (ET)- resistance in estrogen receptor α (ER) expressing breast cancer (BC) is unknown. We tested the hypothesis that inhibition of METTL3, the methyltransferase responsible for the mRNA modification N-6 methyladenosine (m6A), alters m6A modifications and differentially regulates the abundance of mRNA transcripts in ET-sensitive MCF-7 versus resistant LCC9 ER + human BC cells. Differential m6A modifications were identified using direct mRNA sequencing (DRS) performed on five replicates for each cell line ± 1 µM STM2457, a selective METTL3 inhibitor, using Nanopore MinION long read RNA-seq. Parallel short read Illumina RNA-seq quantified differential transcript abundance in the same samples. Selected results were validated by RT-qPCR, m6A-RIP-qPCR, reporter assays, and western blot analysis. Statistical analysis combined m6Anet, a machine-learning algorithm designed to call m6A modified bases, with a generalized linear model following a binomial distribution analysis to identify significant differential m6A modification ratios (DMR). Distinct METTL3 dependent m6A modification patterns in LCC9 and MCF-7 cells were observed in differentially expressed genes (DEG) associated with ET-resistance, including EEF1A2, ACTB, FLNA, PDIA6, AMIGO2, TPT1, XBP1, and CITED4. Select results were validated in additional ET-resistant BC cell lines. m6A-RIP-RT-qPCR validated specific m6A sites. We examined the proximity of m6A sites to estrogen receptor α (ER α)-mRNA binding sites reported in MCF-7 cells. ACTB, PDIA6, and XBP1 demonstrated a short-range proximity, with m6A sites located within 100 bp of ERα binding sites, suggesting a role for m6A in influencing ERα-mRNA binding. Our work provides a framework for integrating DRS and DEG omics data. Our results suggest a role for dysregulation of m6A modifications in pathways implicated in ET resistance in BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA.
- Kentucky IDeA Networks of Biomedical Research Excellence Bioinformatics Core, University of Louisville School of Medicine, Louisville, KY, USA.
- Department of Neuroscience Training, University of Louisville School of Medicine, Louisville, KY, USA.
- Department of Biochemistry and Molecular Genetics, University of Louisville School of Medicine, Louisville, KY, USA. carolyn.klinge@louisville.edu.
- University of Louisville Center for Integrative Environmental Health Sciences (CIEHS), Louisville, KY, USA. carolyn.klinge@louisville.edu.
Förderung
- NIGMS NIH HHS
- NIH HHS
- National Institutes of Health National Institute of General Medical Sciences
- Office of the Assistant Secretary of Defense for Health Affairs Breast Cancer Research Program
- Jewish Heritage Fund
- National Institutes of Health
Zitieren
APA
Petri, B. J., Piell, K. M., Avila-Valdes, B. L., Stanley, C. G., Winkler, L. J., Brown, J. T., Ulett, R., Sanchez, G., Chariker, J. H., Rouchka, E. C., & Klinge, C. M. (2025). Integrated Nanopore and short-read RNA sequencing identifies dysregulation of METTL3- m6A modifications in endocrine therapy- sensitive and resistant breast cancer cells. Functional & Integrative Genomics. https://doi.org/10.1007/s10142-025-01658-2
Vancouver
Petri BJ, Piell KM, Avila-Valdes BL, Stanley CG, Winkler LJ, Brown JT, et al. Integrated Nanopore and short-read RNA sequencing identifies dysregulation of METTL3- m6A modifications in endocrine therapy- sensitive and resistant breast cancer cells. Functional & Integrative Genomics. 2025. doi:10.1007/s10142-025-01658-2
BibTeX
@article{Petri2025,
author = {Petri, Belinda J and Piell, Kellianne M and Avila-Valdes, Bailey L and Stanley, Christian G and Winkler, Laura J and Brown, Johnny Tyler and Ulett, Rye and Sanchez, Gabriela and Chariker, Julia H and Rouchka, Eric C and Klinge, Carolyn M},
title = {Integrated Nanopore and short-read RNA sequencing identifies dysregulation of METTL3- m6A modifications in endocrine therapy- sensitive and resistant breast cancer cells},
journal = {Functional & Integrative Genomics},
year = {2025},
doi = {10.1007/s10142-025-01658-2}
}
EUVIMED